Discover trends, market shifts, and competitive outlooks for the cimzia global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Cimzia Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the Cimzia market has expanded at a brisk pace. It is predicted to grow from $3,030.21 million in 2024 to $3,567.52 million in 2025, boasting a compound annual growth rate (CAGR) of 17.7%. The acceleration observed in the historical phase can be traced back to the uptick in the incidence of autoimmune diseases, the heightened consciousness about biological therapies, the surge in healthcare expenses, the enhanced endorsement of self-injectable biologics, and the expansion of biologic drug manufacturing capability.

Expectations are high for a rapid expansion in the size of the cimzia market over the upcoming years, with a projected growth to $6,776.61 million in 2029 based on a 17.4% compound annual growth rate (CAGR). Factors contributing to the growth during the forecast period include a surge in demand for specific biologics, a rise in patient inclination towards self-administration devices, intensified competition in biosimilars, increased government funding for healthcare, and an emerging focus on personalized medicine. Key trends anticipated in the forecast period involve a transition towards drug delivery solutions centered on patients, increased reliance on digital health tools for disease management, a rise in the application of real-world evidence in drug development, the growth of telemedicine and at-home care solutions, and the incorporation of AI in clinical trials.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19889&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Cimzia Market?

The growing incidence of rheumatoid arthritis is projected to drive the expansion of the cimzia market. Rheumatoid arthritis, a chronic autoimmune disease, causes the immune system to wrongly attack the body’s own joint tissues, resulting in inflammation, discomfort, and joint swelling. The escalating occurrence of this condition can be linked to factors such as an aging population, a rise in genetic susceptibility, environmental factors like smoking and pollution, and enhanced disease awareness and diagnosis. Cimzia plays a critical role in responding to the increasing incidence of rheumatoid arthritis by offering targeted therapy that reduces inflammation, alleviates symptoms, boosts patient’s quality of life, and aids in better disease management. In May 2022, for example, the UK-based Pain Relief Foundation reported that arthritis and musculoskeletal disorders affect over 17 million people, leading to 30 million lost workdays annually in the UK, and chronic pain impacts up to 62% of individuals over 75. Furthermore, in February 2024, the US-based Centers for Disease Control and Prevention reported that the age-adjusted prevalence of diagnosed arthritis in adults aged 18 and older was 18.9% in 2022, with a higher prevalence in women (21.5%) than in men (16.1%). Hence, the surge in rheumatoid arthritis prevalence is fueling the growth of the cimzia market.

Which Key Market Segments Comprise the Cimzia Market and Drive Its Revenue Growth?

The cimziamarket covered in this report is segmented –

1) By Type: Biologics; Biosimilars

2) By Patient Demographics: Adults; Pediatrics

3) By Distribution Channels: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies

4) By Application: Crohn’s Disease; Rheumatoid Arthritis; Ankylosing Spondylitis; Active Psoriatic Arthritis; Axial Spondyloarthritis; Plaque Psoriasis

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19889&type=smp

Which Areas Are Leading Regions in the Cimzia Market Expansion Across the Globe?

North America was the largest region in the cimzia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cimzia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Cimzia Market Over the Coming Years?

A primary advancement within the Cimzia market is the emphasis on creating cutting-edge treatments, like those involving the use of autoimmune therapy solutions, to diversify the available choices for individuals afflicted with non-radiographic axial spondyloarthritis. This action is geared towards resolving an otherwise unaddressed healthcare requirement within the realm of autoimmune disease regulation. Autoimmune therapy solutions are treatments engineered to handle autoimmune conditions by reinstating an equilibrium and tolerance within the immune system, largely through the use of targeted immunotherapies and cellular therapies. For example, UCB, a biopharmaceutical firm based in Belgium, made a significant announcement in July 2024 about the enlargement of the role CIMZIA (certolizumab pegol) will play in treating patients with non-radiographic axial spondyloarthritis (nr-axSpA). The intention of this augmentation is to provide an inventive treatment alternative for individuals who don’t show radiographic proof of the disease despite continuing to display symptoms. CIMZIA is the single biologic with FDA approval for nr-axSpA, underscoring its distinctive role in the realm of autoimmune treatment. This approval introduces a pivotal alternative to conventional therapies, enabling those suffering from this inflammatory disorder to gain better control over symptoms and enhance their quality of life.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cimzia-global-market-report

How Is the Cimzia Market Conceptually Defined?

Cimzia (certolizumab pegol) is a PEGylated monoclonal antibody that targets tumor necrosis factor (TNF), used to reduce inflammation and prevent immune system-related damage in certain autoimmune diseases. It is used in treating moderate to severe rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19889

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model